Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2009-09-01 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2009
Regulatory Filings Classification · 91% confidence The document is a press release dated September 1, 2009, announcing the designation of a new Candidate Drug (CD), MIV-711, for bone diseases. It discusses therapeutic opportunities, existing pipeline candidates (MIV-701, MIV-710), and discontinuation of one compound. This content relates to the company's product development pipeline and strategic focus areas, which falls under general corporate or investor information. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific capital action (CAP). Since it is an announcement about internal drug development progress and pipeline strategy, it best fits the 'Regulatory Filings' (RNS) category as a general corporate announcement that doesn't match the more specific categories like ER, CT, or CAP, or it could be considered a type of Investor Information, but RNS is the most appropriate fallback for non-standard press releases.
2009-09-01 English
Regulatory Filings 2009
Regulatory Filings Classification · 93% confidence The document is a press release dated September 1, 2009, announcing that Medivir has selected an additional drug candidate (MIV-711) targeting cathepsin K for potential use in treating osteoarthritis, rheumatoid arthritis, and bone metastases. This announcement details a strategic development within the company's pipeline, specifically related to drug candidates and therapeutic opportunities. It is not a full annual report (10-K), an earnings release (ER), a formal capital change (CAP), or a management/board change (MANG). Since it is a specific announcement regarding corporate activity and pipeline strategy, and it doesn't fit the definitions for DIV, DIRS, or LTR, it is best classified as a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standard corporate news releases that don't fit the more specific financial or governance codes, although 'Capital/Financing Update' (CAP) could be considered if the pipeline development was directly tied to immediate fundraising, which is not explicitly the primary focus here. However, since this is a strategic pipeline update, and RNS is the fallback for miscellaneous regulatory announcements, RNS is the most appropriate fit among the provided codes for a non-standard press release about drug development strategy.
2009-09-01 Swedish
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a press release dated August 3, 2009, announcing the US FDA approval of the drug Lipsovir®. It details the drug's indication, competitive advantage, and includes an invitation to a teleconference/press conference regarding the approval. This type of announcement, focusing on a significant corporate event (drug approval) and including details for an immediate follow-up call, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a specific, time-sensitive announcement, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally as a Regulatory Filing (RNS) for a non-financial, material event announcement. Given the options, and that it's a material corporate event announcement that doesn't fit the specific financial report categories, RNS is the most appropriate fallback, although ER is sometimes used for major operational news. However, since it is a press release announcing a regulatory milestone (FDA approval) and includes an invitation to a call, it strongly resembles the structure of an Earnings Release announcement, which often includes operational highlights and investor call details. Since it is not explicitly an earnings report, RNS is safer, but given the structure (Press Release + Call Invitation), ER is often used for such material operational news releases. I will classify it as RNS as it is a general regulatory/material announcement not tied to standard financial reporting periods.
2009-08-03 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a press release dated August 3, 2009, announcing that the US FDA has approved the drug Lipsovir® for marketing and sale in the USA. It details the approval (NDA grant) and the specific indication text. It also announces a subsequent conference call regarding this approval. This type of announcement, which is a significant corporate event (regulatory approval) but does not fit neatly into the standard financial reporting categories (like 10-K, ER, or IR), is best classified as a general Regulatory Filing or Announcement. Given the options, 'Regulatory Filings (RNS)' is the most appropriate fallback for significant, non-standard regulatory news that isn't a specific financial report or management change. The document length is short (2539 chars) and it announces an event (the approval) and a follow-up call, rather than being a comprehensive report itself.
2009-08-03 Swedish
Interim / Quarterly Report 2009
Interim / Quarterly Report Classification · 100% confidence The document is a 'halvårsrapport' (half-year report) for Medivir covering the period from January 1 to June 30, 2009. It contains comprehensive financial statements, including income statements, cash flow analysis, and balance sheet data, as well as detailed management commentary on business operations and project portfolios. It is not an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report (IR). H2 2009
2009-07-09 Swedish
Interim / Quarterly Report 2009
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-year Interim Report' for Medivir covering the period 1 January – 30 June 2009. It contains detailed financial statements, including consolidated net sales, loss after tax, cash flow, and balance sheet data, as well as management commentary on business operations and project portfolios. Since it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2009
2009-07-09 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.